EN DE
Watch Onco-Innovations Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Onco-Innovations Limited (ONNVF) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Onco-Innovations Limited stock $0.08, price $0.18, that is 52.2% below the price, quality 27 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Canada

OI Onco-Innovations Limited logo Thin data Nov 10, 2026

Onco-Innovations Limited

ONNVF · US
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Mixed Growth (revenue YoY +69.1 %/yr in USD)
Revenue last quarter 68% below a year ago.
Fair value $0.0843 · Strongly overvalued
Quality 27/100
Negative free cash flow
Trails peers (0/4)
Narrow moat 12/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Onco-Innovations Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3.20 $0.1641 Fair Value $0.0843 Mar 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

19‑month range $0.1641 – $3.20 · fair‑value band $0.0632 – $0.1053 · the $0.1762 price screens above the $0.0843 fair value. As of Nov 10, 2026.

Follow Onco-Innovations in your weekly email

Every Wednesday you see whether Onco-Innovations is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada.

Show moreShow less

The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology.

It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities.

It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.

Stock analysis

Onco-Innovations Limited (ONNVF) currently trades at $0.1762, while our estimate is $0.0843, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0632 (bear) to $0.1053 (bull), the price of $0.1762 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Onco-Innovations Limited reported revenue of C$110K in FY2026 versus C$0 in FY2023. Reported net income was −C$10.8M in FY2026.

Key figures

Market cap $12.2M Micro · EPS (TTM) $−0.1400 · Return on equity −593% · Return on assets (EBIT) −281% (4-year average) · Operating margin −9,432% · Revenue (TTM) C$90.9K · Revenue growth (YoY) −67.8% · Free cash flow −C$5.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 85% below its 52-week high and 7% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −52%, ONNVF screens richer than that median.

Fair Value

Bear $0.0632 Fair Value $0.0843 Bull $0.1053
Price $0.1762 · Downside -52.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ONNVF screens overvalued: fair value 52% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Onco-Innovations Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 0/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −52.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −67.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 44.39× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ONNVF
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ONNVF
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ONNVF
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ONNVF
argenx SE ARGX $971.55 $908.40 −7% vs ONNVF
CSL Limited CSL A$201.68 A$181.40 −10% vs ONNVF
Moderna, Inc MRNA $250.83 $158.70 −37% vs ONNVF
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ONNVF
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ONNVF
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ONNVF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Onco-Innovations Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Onco-Innovations Limited Fair Value". https://www.fairvalue-calculator.com/stock/ONNVF

Frequently asked questions

Is Onco-Innovations Limited (ONNVF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0843 versus a price of $0.1762, about 52% lower (overvalued).
What is the fair value of ONNVF?
Our estimate for Onco-Innovations Limited is $0.0843 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.1762.
What is the quality score of ONNVF?
Onco-Innovations Limited has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Onco-Innovations Limited (ONNVF)?
Our calculated price target is the estimate of $0.0843 (as of Nov 10, 2026). Cautious scenario $0.0632, optimistic scenario $0.1053. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Onco-Innovations Limited stock forecast for 2026?
Our estimate puts fair value at $0.0843, about 52% lower versus a price of $0.1762 (overvalued). Cautious scenario $0.0632, optimistic scenario $0.1053. The calculation is refreshed regularly with new filings.
What is the revenue of Onco-Innovations Limited (ONNVF)?
Onco-Innovations Limited reported trailing-twelve-month revenue of about C$90.9K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Onco-Innovations Limited (ONNVF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Onco-Innovations Limited it is $0.0843 per share (as of Nov 10, 2026), against a price of $0.1762.
Is Onco-Innovations Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ONNVF trades above its calculated fair value: price $0.1762, fair value $0.0843, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONNVF?
No. The price is what the market pays today ($0.1762); the fair value is what the company's own numbers justify ($0.0843). For Onco-Innovations Limited the two are $0.0919 per share apart. That gap is exactly why we show both numbers side by side.
How much is Onco-Innovations Limited worth?
The market values Onco-Innovations Limited at about $12.2M (market capitalisation, as of Nov 10, 2026). Per share that is $0.1762; our models calculate a fair value of $0.0843 per share.
What do the bullish and bearish scenarios say about ONNVF?
Our models span a range for Onco-Innovations Limited: cautious scenario $0.0632, base $0.0843, optimistic $0.1053 per share (as of Nov 10, 2026, price $0.1762). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is ONNVF from its 52-week high?
Onco-Innovations Limited trades at $0.1762, about 85% below its 52-week high of $1.19 and 7% above the low of $0.1641 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0843 is for.
Which stocks are comparable to Onco-Innovations Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Onco-Innovations Limited stock attractive at the current price?
The data as of Nov 10, 2026: price $0.1762, calculated fair value $0.0843 (−52%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Onco-Innovations Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Onco-Innovations Limited (ONNVF)?
The closing price on Nov 6, 2026 was $0.1762. Our estimate is $0.0843, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Onco-Innovations Limited right now?
The price sits above even our optimistic bull case ($0.1053). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Onco-Innovations Limited

How large is the market capitalisation of Onco-Innovations Limited (ONNVF)?
The market capitalisation of Onco-Innovations Limited is $12.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Onco-Innovations Limited (ONNVF)?
Earnings per share at Onco-Innovations Limited are $−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Onco-Innovations Limited (ONNVF)?
The return on equity (ROE) of Onco-Innovations Limited is −593% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Onco-Innovations Limited (ONNVF)?
On an EBIT basis the return on assets of Onco-Innovations Limited is −281% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Onco-Innovations Limited (ONNVF)?
The operating margin of Onco-Innovations Limited is −9,432% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Onco-Innovations Limited (ONNVF)?
Revenue at Onco-Innovations Limited is growing −67.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Onco-Innovations Limited (ONNVF) generate?
The free cash flow of Onco-Innovations Limited is −C$5.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Onco-Innovations Limited in the live analysis

One click puts Onco-Innovations Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.